Dr Reddy’s Laboratories on June 13 said that it has inked agreement with US-based biopharmaceutical organization Gilead Sciences to fabricate and advertise remdesivir – a potential COVID-19 medication in 127 nations, including India. According to the non-selective authorizing understanding, Gilead will allow the Hyderabad-based medication creator the option to enroll and fabricate its investigational tranquilize…